company insight

ICCI – Prague has the green light for medical cannabis

The International Cannabis and Cannabinoids Institute (ICCI) offers a favorable legal climate, a strong professional background and a network of international contacts, experience and experts to its clients.  Its headquarters is in Prague, the capital city of the Czech Republic, a Member State of the European Union. 

SHL Group details its approach to the challenges of emerging formulations

It started as a project uniting outstanding experts from the scientific community, patient organizations and the investment company Dioscorides Global Holdings. As a recognized center of excellence, it cooperates with Charles University, the Czech University of Life Sciences in Prague, Masaryk University in Brno, Mendel University in Brno, Hebrew University in Jerusalem and many other institutions and companies around the world.

ICCI’ primary mission is to research the various uses of medical cannabis and has all the right preconditions for doing so. The team of specialists is comprised of both physicians and experts in healthcare systems, as well as leading experts with direct experience with scientific teams of the United Nations Organization, government bodies and organizations. All of this is supported by strong liaisons with patient organizations. It is this combination of experience and relationships along with a thorough understanding of various methods of treatment with cannabis and cannabinoids that provides ICCI unique know-how to react on the rapid changes in legislative processes in individual nations. ICCI offers deep understanding of the possibilities of medical cannabis for the needs of patients, particularly those that modern medical science may have failed to serve. Our efforts with cannabis-based medicine are always based on the needs of the patient and requirements of the examining physician. Our educational efforts provide the foundation needed for disseminating the knowledge needed by all stakeholders in this dynamic area of medical science and law.

ICCI offers a unique complex opportunity for everyone wanting to understand and utilize the opportunities that medical cannabis offers.

It is a modern hub that brings order to the disruptive technology that medical cannabis represents, and gives it meaning that is both salient and relevant. The expertise of professionals from the International Cannabis and Cannabinoids Institute and the consultative services that they provide are designed and appropriate for investors, physicians and pharmaceutical companies alike. Its advantage is in this comprehensiveness of our team and its activity. We offer to our clients and partners not only the specific experiences of medical cannabis patients, but also that of the physicians who prescribe it and research and development professionals who study this complex herb. Our experience also benefits hospital managers searching for a path towards efficient yet effective treatment. Not the least of which, the International Cannabis and Cannabinoids Institute benefits government bodies and organizations working on legislative processes in their respective countries that aim to make medical cannabis accessible to the public.

ICCI is the largest private investment in the Czech Republic into medical research in recent years. According to ICCI’s cooperating professor, Lubomír Hanuš from Hebrew University in Jerusalem, the potential of medical cannabis is enormous. “We know that marijuana has tetrahydrocannabinol a cannabidiol, but people don’t realize that various chemovars of cannabis may provide different effects,“ he explains. This is indicative of the fact that cannabis holds within further substances that offer anticarcinogenic effects. Through its research efforts, ICCI aids in understanding this plant and preparing from it needed medicine and innovative treatment methods to benefit every patient. Through its knowledge of law and the organization of healthcare systems, ICCI’s experience in this area enables stakeholders to speed up the legislative process by months and years, and their synchronization with the needs of medical science.

The institute thus removes all possible barriers preventing the development of research on the possibilities of medical cannabis and its utilization. Cooperation with the International Cannabis and Cannabinoids Institute enables everyone with an interest in researching medical cannabis to gain the background and facilities of a top international team, patient experiences and the organizational background of a strong scientific institution.

The Prague institute is a unique place for those who see the future of medical science in the area of biomedicine, and are searching for a platform for investment, sharing, development or education in this area. Thus, in golden Prague, the green light shines for everyone wanting to quickly forge a pathway to the future.

Share this article

Go to article: Home | Gut InstinctGo to article: In this issueGo to article: TSS Company InsightGo to article: TSS ABGo to article: International Cannabis and Cannabinoid Institute (ICCI) Company InsightGo to article: International Cannabis and Cannabinoid Institute (ICCI)Go to article: ContentsGo to article: Daiichi JitsugyoGo to article: NewsGo to article: Scandinavian Health Ltd.Go to article: The Pharma Industry BriefingGo to article: Komtur PharmaceuticalsGo to article: Komtur Pharmaceuticals Company InsightGo to article: How will the UK’s relaxed cannabis regulations impact clinical practice?Go to article: Finnair CargoGo to article: Finnair Cargo | Company InsightGo to article: Developing a new class of cancer combo drugsGo to article: Phoenix Company InsightGo to article: PhoenixGo to article: Antidepressants in the environment: combatting pharmaceutical pollutionGo to article: AtoZ-CRO GmbHGo to article: AtoZ-CRO GmbH Company InsightGo to article: Christensella: the key to unlocking gut microbiome-based drug discovery?Go to article: CBDepotGo to article: CBDepot Company InsightGo to article: Going digital to improve clinical trial enrolmentGo to article: BEAGo to article: Incretin combination therapy: a breakthrough for type 2 diabetes?Go to article: AlpexGo to article: Ebola in the DRC: vaccinating in a conflict zoneGo to article: Hemp IndustriesGo to article: Unither PharmaceuticalsGo to article: Data overload: turning challenges into opportunities in clinical trialsGo to article: ZenatekGo to article: Solving clinical research challenges: an IT perspectiveGo to article: Pfanstiehl Company InsightGo to article: PfanstiehlGo to article: EventsGo to article: In the next issue